ImmunityBio is a brand dedicated to conquering cancer through the development of innovative therapies that target and kill disease while preserving the immune system. They offer a range of investigational immunotherapy and cell therapy products designed to strengthen each patient's natural immune system, enabling it to outsmart and eliminate cancerous or infected cells. ImmunityBio's comprehensive immunotherapy approach combines activation of natural killer (NK) cells, T cells, and macrophages with the establishment of immune memory by dendritic cells.

They also utilize their neoepitope prediction pipeline to develop personalized cancer vaccines. Clinical trials are currently underway to assess the safety and effectiveness of these therapies across various tumor types. Additionally, ImmunityBio is researching potential viral therapies for conditions like HIV and developing vaccines to eradicate viral infections and reduce the risk of associated cancers.

With a robust clinical pipeline and a commitment to increasing diversity in clinical trials, ImmunityBio is at the forefront of advancing immunotherapy and providing targeted solutions to empower patients in their fight against cancer